Aviva PLC Grows Stock Holdings in Insulet Co. (NASDAQ:PODD)

Aviva PLC grew its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 164.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 42,276 shares of the medical instruments supplier's stock after buying an additional 26,294 shares during the quarter. Aviva PLC owned approximately 0.06% of Insulet worth $11,037,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Norges Bank bought a new position in Insulet during the 4th quarter worth $248,806,000. Raymond James Financial Inc. bought a new stake in Insulet in the fourth quarter worth approximately $69,433,000. Alecta Tjanstepension Omsesidigt bought a new position in shares of Insulet during the 4th quarter worth approximately $53,184,000. Artisan Partners Limited Partnership grew its position in shares of Insulet by 24.1% during the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock worth $201,073,000 after buying an additional 149,524 shares during the period. Finally, Proficio Capital Partners LLC bought a new stake in shares of Insulet in the 4th quarter valued at $28,422,000.

Wall Street Analyst Weigh In

PODD has been the subject of several research analyst reports. Wells Fargo & Company lifted their price target on shares of Insulet from $305.00 to $322.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Raymond James reaffirmed an "outperform" rating and issued a $328.00 target price (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Citigroup increased their price target on Insulet from $310.00 to $355.00 and gave the stock a "buy" rating in a report on Friday, February 21st. TD Cowen boosted their price objective on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a report on Friday, January 3rd. Finally, Royal Bank of Canada began coverage on Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $292.06.

Remove Ads

Insider Buying and Selling

In other news, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company's stock, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at $888,525. This represents a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Insulet Stock Performance

Shares of NASDAQ:PODD traded up $0.91 during trading on Monday, hitting $254.90. 49,395 shares of the company were exchanged, compared to its average volume of 716,363. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The stock has a 50 day moving average of $266.67 and a 200 day moving average of $260.56. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company has a market cap of $17.90 billion, a PE ratio of 44.02, a P/E/G ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. As a group, equities research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.